$ANVS News

Roth Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation

Roth Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $8

Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Annovis Bio (ANVS) Price Target Decreased by 12.23% to 14.02

Annovis Bio Regains NYSE Listing Compliance

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Bio Prices Underwritten Public Offering Of 7,895,000 Shares And Warrants To Purchase Up To 7,105,500 Shares At $1.90 Per Unit

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Annovis Bio Announces New Publication Titled Buntanetap Treatment In Mild To Moderate Alzheimer's Disease: Phase 2/3 Study In Peer-Reviewed Journal Nature NPJ Dementia

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Bio Closes Underwritten Public Offering Raising ~$10M In Gross Proceeds; Financing Secures Path To First NDA Submission For Buntanetap

Annovis Bio (ANVS) Price Target Increased by 13.94% to 15.98

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.